Endometrial thinning

Endometrial thinning refers to a pathological condition characterized by an abnormally thin endometrium—typically defined as less than 7 mm in thickness during the window of implantation—which is associated with reduced fertility and poor pregnancy outcomes. It is not a single molecular target but rather a clinical phenotype resulting from complex cellular and molecular alterations. Key features include impaired cell proliferation, increased cellular senescence marked by altered p16/p21 expression, excessive collagen deposition leading to fibrosis, downregulation of genes involved in glycolysis/gluconeogenesis and the cell cycle in epithelial cells, decreased immune cell infiltration (T cells, NK cells), aberrant activation/inhibition of signaling pathways such as SEMA3/EGF/PTN/TWEAK, and changes in hormone receptor expression. The pathogenesis may involve vascular impairment or prior uterine injury. Therapeutic approaches focus on promoting regeneration using hormones (estrogen), growth factors like G-CSF or EGF/FGF/PDGF/MMP3 proteins delivered via stem cell secretomes or direct stem/progenitor cell transplantation; however, these are not directed at a specific molecular target but aim to restore normal tissue architecture and function[1][3][5][7]. Endometrial thinning should not be considered a canonical therapeutic target such as an enzyme or receptor; rather it is a disease state involving multiple pathways. Therefore "endometrial thinning" itself does not fit standard drug-target classification schemes—it is more accurately described as a clinical syndrome with multifactorial etiology than as an individual molecule/receptor suitable for structured drug targeting[1][3].

Other names

Thin endometriumTEEndometrial atrophy

Promotion of endometrial proliferation and repair via hormonal stimulation or growth factor signaling[7] Anti-fibrotic effects through modulation of myofibroblast activity and extracellular matrix deposition[7]